WCN26-2473 Protocol and Enrollment Status of the START-HOP Trial: A Randomized Study of Twice-Weekly Teriparatide in Hemodialysis Patients with Osteoporosis

Read full text Summarise with VIRAT
Authors: Michiko Kurotori, Daigo Nakazawa, Kanako Watanabe‐Kusunoki, Fumihiko Hattanda, Saori Nishio, Tatsuya Atsumi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Patients with chronic kidney disease (CKD), particularly those undergoing hemodialysis (HD), are at increased risk of bone fractures, primarily due to CKD-mineral and bone disorder (CKD-MBD). Although secondary hyperparathyroidism (SHPT) can be managed using vitamin D analogs and calcimimetics, fracture risk remains elevated, highlighting the need for direct therapeutic interventions targeting bone density and quality. Unlike in the general population, treatment for osteoporosis has not yet been established for HD patients.

Fields of Study & Subjects

Bone health and osteoporosis research Parathyroid Disorders and Treatments Dialysis and Renal Disease Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105193–105193
Publication date
25 March 2026
Language
EN